The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Links

 

Gene Review

MN1  -  meningioma (disrupted in balanced...

Homo sapiens

Synonyms: MGCR, MGCR1, MGCR1-PEN, dJ353E16.2
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of MN1

 

High impact information on MN1

  • We have mapped the disease locus (DM2) of the MN1 family to a 10-cM region of chromosome 3q [6].
  • In conclusion, our data suggest MN1 overexpression as a new prognostic marker in AML with normal cytogenetics [7].
  • MN1 was highly expressed in some patients with acute lymphoblastic but not chronic lymphocytic or myeloid leukemia [7].
  • Here we addressed the role of MN1-TEL in myeloid leukemogenesis using the same mouse model [8].
  • Enforced expression of MN1-TEL in multipotent hematopoietic progenitors in knock-in mice perturbed growth and differentiation of myeloid as well as lymphoid cells [8].
 

Chemical compound and disease context of MN1

 

Biological context of MN1

  • Cloning and characterization of MN1, a gene from chromosome 22q11, which is disrupted by a balanced translocation in a meningioma [2].
  • The 1,25(OH)2D3-regulated transcription factor MN1 stimulates vitamin D receptor-mediated transcription and inhibits osteoblastic cell proliferation [10].
  • The MN1 gene spans about 70 kb and consists of at least two large exons of approximately 4.7 kb and 2.8 kb [2].
  • The MN1 cDNA codes for a protein of 1319 amino acids when the first methionine in the open reading frame is used [2].
  • Furthermore, forced expression of MN1 in osteoblastic cells results in a profound decrease in cell proliferation by slowing S-phase entry, suggesting that MN1 is an antiproliferative factor that may mediate 1,25-(OH)2D3-dependent inhibition of cell growth [10].
 

Anatomical context of MN1

  • MN1-TEL-transduced BM showed increased self-renewal capacity of primitive progenitors in vitro, and prolonged in vitro culture of MN1-TEL-expressing BM produced immortalized myeloid, interleukin (IL)-3/stem cell factor-dependent cell lines with a primitive morphology [1].
  • We determined the transforming activity of MN1-TEL in mouse bone marrow (BM) by using retroviral transfer [1].
  • Collectively, these data indicate that MN1 is a 1,25-(OH)2D3-induced VDR coactivator that also may have critical roles in modulating osteoblast proliferation [10].
 

Associations of MN1 with chemical compounds

  • The N-terminal MN1 moiety is rich in proline residues and contains two polyglutamine stretches, suggesting that MN1-TEL may act as a deregulated transcription factor [11].
  • In this study, we characterize the regulation and function of MN1, a novel 1,25-(OH)2D3-induced gene in osteoblastic cells [10].
  • Our studies demonstrate that MN1 preferentially stimulates VDR-mediated transcription through its ligand-binding domain and synergizes with the steroid receptor coactivator family of coactivators [10].
  • On the other hand, we show that induction of the promoter by RA depends on co-expressed MN1 in Hep3B cells [12].
  • We were unable to confirm the effect of Pg on the promoter in Hep3B and U2-osteosarcoma cells regardless of the presence of MN1 [12].
  • The differentiation block could be released by fusion of a transcriptional activator (VP16) to MN1 without affecting the ability to immortalize BM cells, suggesting that MN1 blocks differentiation by transcriptional repression [13].
 

Regulatory relationships of MN1

 

Other interactions of MN1

  • In this article, we describe the coordinated expression of IGFBP5 and MN1 in meningiomas [12].
  • Overexpressed BAALC, ERG and MN1 genes and expression of breast cancer resistance protein have been shown to confer poor prognosis [14].
  • This observation prompted us to investigate the regional variation in the extent of LD more systematically and we selected an isochore transition within the MN1/PITPNB gene region on chromosome 22q12 [15].
  • In both cases, the NF1 and the MN1/PITPNB gene region, a clear-cut transition of the long-range GC content precisely coincides with a change in the extent of observable LD [15].
 

Analytical, diagnostic and therapeutic context of MN1

  • Transplantation of such cell lines into lethally irradiated mice rescued them from irradiation-induced death and resulted in the contribution of MN1-TEL-expressing cells to all hematopoietic lineages, underscoring the primitive nature of these cells and their capacity to differentiate in vivo [1].
  • No MN1-TEL fusion could be detected upon RT-PCR analysis, in contrast to the previously investigated t(12;22) [16].
  • Anorectal manometry was performed preoperatively (MN1) and postoperatively, before (MN2) and after (MN3) ileostomy closure [17].

References

  1. MN1-TEL, the product of the t(12;22) in human myeloid leukemia, immortalizes murine myeloid cells and causes myeloid malignancy in mice. Carella, C., Bonten, J., Rehg, J., Grosveld, G.C. Leukemia (2006) [Pubmed]
  2. Cloning and characterization of MN1, a gene from chromosome 22q11, which is disrupted by a balanced translocation in a meningioma. Lekanne Deprez, R.H., Riegman, P.H., Groen, N.A., Warringa, U.L., van Biezen, N.A., Molijn, A.C., Bootsma, D., de Jong, P.J., Menon, A.G., Kley, N.A. Oncogene (1995) [Pubmed]
  3. Translocation (12;22) (p13;q11) in myeloproliferative disorders results in fusion of the ETS-like TEL gene on 12p13 to the MN1 gene on 22q11. Buijs, A., Sherr, S., van Baal, S., van Bezouw, S., van der Plas, D., Geurts van Kessel, A., Riegman, P., Lekanne Deprez, R., Zwarthoff, E., Hagemeijer, A. Oncogene (1995) [Pubmed]
  4. TEL and MN1 fusion in myelodysplastic syndrome: new evidence for a therapy-related event. Vieira, L., Marques, B., Ambrósio, A.P., Chumbo, M., Reis, A.B., Júnior, E.C., Boavida, M.G. Br. J. Haematol. (2000) [Pubmed]
  5. Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics. Galmarini, C.M., Kamath, K., Vanier-Viornery, A., Hervieu, V., Peiller, E., Falette, N., Puisieux, A., Ann Jordan, M., Dumontet, C. Br. J. Cancer (2003) [Pubmed]
  6. Genetic mapping of a second myotonic dystrophy locus. Ranum, L.P., Rasmussen, P.F., Benzow, K.A., Koob, M.D., Day, J.W. Nat. Genet. (1998) [Pubmed]
  7. High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Heuser, M., Beutel, G., Krauter, J., D??hner, K., von Neuhoff, N., Schlegelberger, B., Ganser, A. Blood (2006) [Pubmed]
  8. Conditional MN1-TEL knock-in mice develop acute myeloid leukemia in conjunction with overexpression of HOXA9. Kawagoe, H., Grosveld, G.C. Blood (2005) [Pubmed]
  9. Labd-14-ene-8,13-diol (sclareol) induces cell cycle arrest and apoptosis in human breast cancer cells and enhances the activity of anticancer drugs. Dimas, K., Papadaki, M., Tsimplouli, C., Hatziantoniou, S., Alevizopoulos, K., Pantazis, P., Demetzos, C. Biomed. Pharmacother. (2006) [Pubmed]
  10. The 1,25(OH)2D3-regulated transcription factor MN1 stimulates vitamin D receptor-mediated transcription and inhibits osteoblastic cell proliferation. Sutton, A.L., Zhang, X., Ellison, T.I., Macdonald, P.N. Mol. Endocrinol. (2005) [Pubmed]
  11. The MN1-TEL fusion protein, encoded by the translocation (12;22)(p13;q11) in myeloid leukemia, is a transcription factor with transforming activity. Buijs, A., van Rompaey, L., Molijn, A.C., Davis, J.N., Vertegaal, A.C., Potter, M.D., Adams, C., van Baal, S., Zwarthoff, E.C., Roussel, M.F., Grosveld, G.C. Mol. Cell. Biol. (2000) [Pubmed]
  12. The MN1 oncoprotein activates transcription of the IGFBP5 promoter through a CACCC-rich consensus sequence. Meester-Smoor, M.A., Molijn, A.C., Zhao, Y., Groen, N.A., Groffen, C.A., Boogaard, M., van Dalsum-Verbiest, D., Grosveld, G.C., Zwarthoff, E.C. J. Mol. Endocrinol. (2007) [Pubmed]
  13. MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. Heuser, M., Argiropoulos, B., Kuchenbauer, F., Yung, E., Piper, J., Fung, S., Schlenk, R.F., Dohner, K., Hinrichsen, T., Rudolph, C., Schambach, A., Baum, C., Schlegelberger, B., Dohner, H., Ganser, A., Humphries, R.K. Blood (2007) [Pubmed]
  14. Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances. Mrózek, K., Döhner, H., Bloomfield, C.D. Curr. Opin. Hematol. (2007) [Pubmed]
  15. Long-range sequence composition mirrors linkage disequilibrium pattern in a 1.13 Mb region of human chromosome 22. Eisenbarth, I., Striebel, A.M., Moschgath, E., Vogel, W., Assum, G. Hum. Mol. Genet. (2001) [Pubmed]
  16. Analysis of TEL proteins in human leukemias. Poirel, H., Lacronique, V., Mauchauffé, M., Le Coniat, M., Raffoux, E., Daniel, M.T., Erickson, P., Drabkin, H., MacLeod, R.A., Drexler, H.G., Ghysdael, J., Berger, R., Bernard, O.A. Oncogene (1998) [Pubmed]
  17. Recovery of anal sphincter function after the ileoanal reservoir procedure in patients over the age of fifty. Jorge, J.M., Wexner, S.D., James, K., Nogueras, J.J., Jagelman, D.G. Dis. Colon Rectum (1994) [Pubmed]
 
WikiGenes - Universities